Filing Details
- Accession Number:
- 0001479290-24-000074
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-17 16:34:50
- Reporting Period:
- 2024-04-16
- Accepted Time:
- 2024-04-17 16:34:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1479290 | Revance Therapeutics Inc. | RVNC | Pharmaceutical Preparations (2834) | 770551645 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
2012846 | Erica Jordan | C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-04-16 | 2,392 | $3.80 | 114,864 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") granted on April 3, 2023 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding thenumber of shares sold at each separate price.